Semaglutide and tirzepatide reshaped obesity medicine, but they are the first generation of a much larger wave. Oral pills that avoid injections entirely, triple agonists targeting three receptors at once, and combinations pairing a GLP-1 with amylin analogues are all moving through development and, in some cases, into pharmacies. Here is what is coming, what each approach does differently, and what it might mean for food noise specifically.
Why a second generation was inevitable
The first generation solved the central problem — these drugs work, dramatically, for weight and for the intrusive food thoughts that accompany it. But they left several problems unsolved, and each of those problems is now the target of a development programme.
- They require weekly injections, which a substantial minority of people will simply not do.
- They are expensive to manufacture and price, limiting access.
- Gastrointestinal side effects cause many patients to abandon treatment during titration.
- A meaningful proportion of patients plateau below their goal on the maximum dose.
- Weight loss comes with lean mass loss that current drugs do nothing to prevent.
Oral GLP-1s: removing the needle
The most consequential near-term development is the arrival of effective oral GLP-1s. Needle aversion is not a marginal preference — it keeps a large number of people from ever starting treatment, and those people have the same food noise as everybody else.
Oral semaglutide already exists in tablet form and has moved into direct manufacturer channels and retail telehealth at prices competitive with compounded injectables. Eli Lilly's oral GLP-1 programme, orforglipron, is a small molecule rather than a peptide, which matters enormously for manufacturing: small molecules are cheaper to produce at scale and do not carry the strict empty-stomach dosing requirements that peptide tablets do.
Why the small-molecule distinction matters
Peptide-based oral semaglutide must be taken on an empty stomach with plain water and a wait before eating, because absorption is otherwise poor. A small-molecule oral drug does not face the same constraint, which removes both a daily inconvenience and a major source of patients accidentally underdosing themselves.
Triple agonists: adding glucagon
Semaglutide targets the GLP-1 receptor. Tirzepatide targets GLP-1 and GIP, and the addition of GIP is widely credited for its stronger effect on both weight and appetite. Retatrutide adds a third target — the glucagon receptor — producing a triple agonist.
Glucagon receptor activity is interesting because it increases energy expenditure rather than only reducing intake. In principle that addresses one of the frustrations of current drugs: they work almost entirely by making you eat less, and metabolic adaptation gradually works against that.
Trial results for triple agonists have shown weight reductions beyond what tirzepatide achieves. Whether that translates into proportionally greater food noise relief is a separate question — appetite suppression and the quieting of intrusive food thoughts are related but not identical, and the second has been measured far less rigorously than the first.
Amylin combinations: a different mechanism entirely
CagriSema pairs semaglutide with cagrilintide, an amylin analogue. Amylin is a hormone co-secreted with insulin that signals satiety through a pathway distinct from GLP-1, which means the combination attacks appetite from two directions rather than pushing harder on one.
Survodutide, a GLP-1 and glucagon dual agonist, takes yet another combination approach. The broader pattern across all of these programmes is the same: rather than escalating the dose of a single mechanism, combine mechanisms that work differently.
For patients who plateau on current drugs — and plateauing with food noise creeping back is a common and demoralising experience — multi-mechanism approaches are the most promising development in the pipeline.
What this means for food noise specifically
Three implications are worth drawing out, and they matter differently depending on your situation.
- 1
Access is about to widen substantially
Cheaper, orally available drugs will reach people who have been excluded by cost or by needle aversion. If you have food noise and have ruled out treatment for either reason, that calculation is changing.
- 2
Plateau may become a solvable problem
Multi-mechanism drugs give patients who stall on tirzepatide somewhere else to go, rather than the current situation where the maximum dose of the strongest available drug is the end of the road.
- 3
Tolerability should improve
Several programmes are explicitly targeting the gastrointestinal side effects that cause patients to abandon treatment during titration — which is exactly when food noise relief is starting to arrive.
A caution worth stating: none of this is a reason to delay treatment you need now. Pipeline drugs arrive later than expected, cost more than hoped at launch, and take years to become widely accessible. If a currently available medication would help your food noise, waiting for a better one is usually the wrong trade.
Key Takeaways
- →Oral GLP-1s are the most immediately consequential development, because needle aversion excludes many people from treatment entirely.
- →Small-molecule oral drugs avoid the strict dosing conditions that peptide tablets require, removing a common cause of accidental underdosing.
- →Triple agonists add glucagon receptor activity, which increases energy expenditure rather than only reducing intake.
- →Amylin combinations attack appetite through a second, distinct pathway rather than pushing harder on one.
- →Multi-mechanism drugs are the most promising answer for patients who plateau with food noise creeping back.
- →Do not delay treatment you need now waiting for a pipeline drug — they arrive late and cost more than expected.
Frequently Asked Questions
What is orforglipron?+
It is Eli Lilly's oral GLP-1 programme, based on a small molecule rather than a peptide. That distinction matters because small molecules are cheaper to manufacture at scale and do not require the strict empty-stomach dosing conditions that peptide-based oral semaglutide does.
Is retatrutide better than tirzepatide?+
Trial results for triple agonists have shown weight reductions beyond what tirzepatide achieves, driven partly by glucagon receptor activity that increases energy expenditure. Whether that translates into proportionally greater food noise relief is less well established, since appetite suppression and intrusive food thoughts are related but distinct.
What is CagriSema?+
A combination of semaglutide with cagrilintide, an amylin analogue. Amylin signals satiety through a pathway distinct from GLP-1, so the combination targets appetite from two directions rather than escalating a single mechanism.
Should I wait for a newer drug?+
Generally no. Pipeline medications consistently arrive later than expected, launch at high prices, and take years to become broadly accessible. If a currently available medication would meaningfully reduce your food noise, the cost of waiting is usually higher than the benefit.
Will these drugs be cheaper?+
Small-molecule oral drugs should be substantially cheaper to manufacture than injectable peptides, and increased competition between manufacturers has already been driving self-pay prices down. But launch pricing is set by market conditions rather than manufacturing cost, so expect improvement over time rather than immediately.
Will newer drugs help if I plateaued?+
This is the most promising aspect of the pipeline for existing patients. Multi-mechanism drugs give people who stall on the maximum dose of current medication a genuinely different lever to pull, rather than the current dead end.
Looking for a provider?
We have reviewed 167 GLP-1 providers and ranked them by category:
Related Reading
This article is educational content, not medical advice. GLP-1 medications require a prescription and clinical supervision — talk to a licensed clinician about whether treatment is appropriate for you. See our medical disclaimer.